Literature DB >> 8244540

Caveat surgeon: do orthopaedic surgeons take adequate precautions against blood-borne viral infections, in particular the human immunodeficiency virus (HIV)?

D K Asante1, G R Tait.   

Abstract

One year ago the British Orthopaedic Association issued guidelines for the prevention of cross-infection with special reference to HIV and the hepatitis viruses. We were interested to establish whether the guidelines were being widely applied and whether they had changed general orthopaedic practice. We distributed a questionnaire to Scottish Orthopaedic Fellows, Associates of the BOA, and orthopaedic trainees. With a 70 per cent return rate, it would appear that the recommendations are not adhered to in full. Of respondents, 84 per cent were immunized or undergoing immunization against hepatitis B. In all, 30 per cent were operating on high-risk patients on a monthly basis, 60 per cent thought that their current practice was low risk, and only 15 per cent thought that their future practice would be high risk; 81 per cent were concerned and yet only 60 per cent had altered their practice. It is of some concern that orthopaedic surgeons may not take the threat of HIV cross-infection seriously enough and do not consider precautions mandatory. Further pressure and support from the BOA may be necessary to encourage a change in orthopaedic practice as the threat of HIV is increasing.

Entities:  

Mesh:

Year:  1993        PMID: 8244540     DOI: 10.1016/0020-1383(93)90024-z

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  2 in total

1.  Barrier methods in the operating room: surgical habits die hard.

Authors:  B Karagkevrekis; D Warwick; B Freeman
Journal:  Ann R Coll Surg Engl       Date:  1997-03       Impact factor: 1.891

2.  Perceptions of orthopaedic surgeons regarding hepatitis C viral transmission: a questionnaire survey.

Authors:  G C Wallis; W Y Kim; B R Chaudhary; J J Henderson
Journal:  Ann R Coll Surg Engl       Date:  2007-04       Impact factor: 1.891

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.